TY - JOUR
A1 - Lavekar, G
A1 - Ravishankar, B
A1 - Gaidhani, S
A1 - Shukla, V
A1 - Ashok, B
A1 - Padhi, M
T1 - Mahayograj guggulu: Heavy metal estimation and safety studies
Y1 - 2010/7/1
JF - International Journal of Ayurveda Research
JO - Int J Ayurveda Res
SP - 150
EP - 158
VL - 1
IS - 3
UR - http://www.ijaronline.com/article.asp?issn=0974-7788;year=2010;volume=1;issue=3;spage=150;epage=158;aulast=Lavekar
DO - 10.4103/0974-7788.72486
N2 - Objective: This study was conducted to estimate the heavy metal profile and determine the safety of Mahayograj guggulu, an Ayurvedic herbo-mineral preparation. Design:Mahayograj guggulu, manufactured by Shree Baidynath Ayurved Bhawan Pvt. Ltd., Gwalior Road, Jhansi - 284 003 (of batch number-07 and manufacturing date October 2004) was procured from the local market. Heavy metal concentrations were measured using an atomic absorption spectrophotometer. A total of 40 Charles Foster strain albino rats of either sex with an average body weight of 160-250 g were divided into four groups (Groups I, II, III and IV), with 10 animals in each group. Group I served as the control, while Group II, III and IV rats received Mahayograj guggulu at a dose of 54 (dose equivalent to human therapeutic dose), 270 (five-times the dose equivalent to the human therapeutic dose) and 540 (10-times the dose equivalent to human therapeutic dose) mg/kg, p.o. for 120 days. The effect of drug administration was noted on the ponderal, biochemical, hematological and histopathological parameters. In addition, urine examination was also carried out. At the end of the study, only six rats per group were sacrificed as per the IAEC advice. Results:Mahayograj guggulu was found to be safe at all dose levels tested. No significant behavioral changes were noted in any of the groups studied. The effect on food and water consumption and fecal and urine output remained unaffected in all groups during the study period. No major alterations were observed in hematology, serum biochemistry, necropsy and histopathology at the therapeutically advocated dose level. Heavy metal content measurement indicated levels of 25.8 μg/g for lead, 0.07 μg/g for mercury and 5.19 μg/g for arsenic. Conclusions: The test drug is well tolerated as no changes of a serious nature could be observed in any of the parameters assessed.
ER -